BlackRock
ZVSA

BlackRock’s ZyVersa Therapeutics ZVSA Stock Holding History

BlackRock’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14
Closed -$50K – 5855
2022
Q3 		$50K Hold
14
– – ﹤0.01% 5357
2022
Q2 		$50K Buy
+14
New +$48.7K ﹤0.01% 5414

Other funds holding ZVSA

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

BlackRock's ZVSA Position: Q4 2022 in Review

BlackRock sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 14 shares — an estimated $50K sold.

BlackRock first reported a position in ZVSA in Q2 2022 and held it in 2 quarters. The position peaked at $50K in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

  • BlackRock reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 14 ZyVersa Therapeutics shares in Q4 2022, an estimated $50K.
  • BlackRock first reported a position in ZyVersa Therapeutics in Q2 2022 and held it in 2 quarters.
  • BlackRock's ZyVersa Therapeutics position peaked at $50K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.